Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Mitsubishi Tanabe Pharma
Biotech
Dewpoint collects new pharma partner for preclinical ALS program
Mitsubishi Tanabe Pharma is offering Dewpoint Therapeutics up to $480 million biobucks in a new research pact centering around an ALS program.
Gabrielle Masson
Dec 4, 2024 11:47am
Regeneron scratches 2 drugs from pipeline
Nov 3, 2022 11:05am
Mitsubishi Tanabe, EditForce sign $146M CNS gene therapy deal
Jul 5, 2022 9:20am
Coya Therapeutics eyes IPO, 2022 trial for ALS hopeful
Aug 3, 2021 11:37am
Salix grabs ex-Asia rights to Mitsubishi Tanabe autoimmune drug
Apr 25, 2019 9:10am
Akebia’s Japanese vadadustat data ‘bode well’ for larger trials
Mar 13, 2019 11:16am
